This is a non-core endpoint: only basic statistics are computed.
Benign neoplasm: Testis
CD2_BENIGN_TESTIS_EXALLC
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
|
1. Apply sex-specific ruleonly males |
- |
2. Check conditionsNone |
|
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
- |
4. Check minimum number of eventsNone |
- |
5. Include endpointsNone |
- |
6. Filter based on genotype QC (FinnGen only)None |
- |
Control definitions (FinnGen only)
- Control exclude
- C3_CANCER, C3_CANCER_WIDE
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D29
- Name in latin
- Neoplasma benignum testis
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Testis
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm: Testis
- Benign neoplasm of male genital organs
- Benign neoplasm of male genital organs
- Benign neoplasms
- Benign neoplasms
Similar with less cases:
Case counts by codes
↥FinnGen case counts by registry codes:
No upset plot: script not run.
No upset table: script not run.
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 159 | - | 159 |
| Unadjusted period prevalence (%) | 0.07 | - | 0.07 |
| Median age at first event (years) | 47.14 | - | 47.14 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 139
- Matched controls
- 1390
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D29.2
ICD-10 Finland
Benign neoplasm: Testis
+∞
129.0
103
*
KFC00
NOMESCO Finland
Unilateral orchiectomy
211.8
44.7
44
*
D40.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Testis
124.4
35.7
37
*
22200
ICD-8 Finland
Benign neoplasm of male genital organs, Testis
+∞
24.7
23
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
204.6
17.9
18
*
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
15.6
17.1
28
22
130
Kela drug reimbursment
Malignant tumour
+∞
17.0
16
*
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
17.0
16
*
KFA00
NOMESCO Finland
Exploration of testis
166.4
14.7
15
*
9061/3-C62.9
ICD-O-3
Seminoma, NOS, of testis, NOS
+∞
13.8
13
*
2220A
ICD-9 Finland
Benign neoplasm of male genital organs, Testis
+∞
13.8
13
*
C62.11
ICD-10 Finland
Malignant tumor of the descending testicle, seminoma
+∞
12.7
12
*
JN4BD
NOMESCO Finland
Extensive body CT
10.9
12.6
24
26
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
11.6
11
*
A04AA02
ATC
granisetron; systemic, transdermal
+∞
11.6
11
*
116
Kela drug reimbursment
Prostate cancer
+∞
9.5
9
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
+∞
9.5
9
*
A03FA01
ATC
metoclopramide; systemic, rectal
6.2
9.0
24
45
N02AA05
ATC
oxycodone; systemic
5.2
8.7
27
61
H02AB02
ATC
dexamethasone; systemic
29.5
8.6
11
*
7501
FHL
Testicular exploration (includes removal of biopsy, detorsion or appendix test)
84.2
7.5
8
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
7.3
7
*
KCD02
NOMESCO Finland
Transurethral resection of bladder
42.1
6.8
8
*
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
+∞
6.3
6
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
6.3
6
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
6.3
6
*
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
+∞
6.3
6
*
WF002
NOMESCO Finland
Radical radiotherapy
+∞
6.3
6
*
D29.4
ICD-10 Finland
Benign neoplasm: Scrotum
+∞
6.3
6
*
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
44
158
3.47
10.21
2.8
2.5
12.1
15.5
nmol/l
1.78
38
146
66
441
1.85
3.43
4.1
3.9
—
—
—
0
0
10
27
3.89
3.41
1.4
2.3
98.3
78.4
%
—
10
27
22
99
2.42
3.24
4.4
2.8
—
—
—
0
0
59
387
1.83
3.21
3.9
3.0
—
—
—
0
0
16
68
2.50
2.65
1.4
2.1
30.1
38.0
nmol/l
1.01
16
68
46
296
1.78
2.60
3.9
2.6
0.8
0.4
e6/l
0.33
37
214
8
21
3.95
2.50
1.1
1.2
—
—
—
0
0
10
35
2.98
2.35
1.2
1.8
2.0
3.7
mg/l
—
10
24
100
807
1.64
2.34
5.1
3.7
3.6
2.0
ug/l
0.41
88
725
103
847
1.61
2.15
8.4
5.4
73.2
73.7
u/l
0.06
97
786
16
76
2.23
2.11
4.5
2.3
63.3
61.0
ml/min/173m2
—
6
35
17
86
2.09
1.93
1.6
1.9
—
—
—
0
0
18
97
1.96
1.74
2.1
1.9
—
—
—
0
0
29
184
1.70
1.70
1.9
2.0
31.4
29.7
s
0.75
29
178
65
505
1.49
1.61
10.0
6.8
1.2
1.2
mmol/l
0.36
53
428
75
601
1.47
1.59
10.5
6.5
4.4
4.5
e9/l
0.06
69
536
35
239
1.60
1.55
3.0
3.6
227.2
302.2
ng/l
0.14
28
188
52
392
1.49
1.48
2.6
2.3
178.3
175.0
ug/l
0.03
47
359
39
277
1.54
1.46
4.6
3.4
0.0
0.1
estimate
0.68
15
73
6
22
2.79
1.45
1.0
1.2
—
—
—
0
0
6
22
2.79
1.45
1.0
1.2
—
—
—
0
0
7
29
2.48
1.41
1.9
3.1
3.3
4.2
g/l
—
7
29
7
29
2.48
1.41
1.9
1.3
—
—
—
0
0
5
17
3.00
1.37
1.0
1.1
—
—
—
0
0
126
1149
1.47
1.14
17.0
12.5
32.4
26.4
mg/l
0.80
102
894
20
129
1.63
1.12
1.4
1.7
—
—
—
0
0
5
21
2.42
1.10
2.8
2.8
—
—
—
0
0
55
443
1.37
1.05
3.1
2.6
0.7
0.8
ug/l
0.55
36
288
5
22
2.31
1.04
1.0
1.0
—
—
—
0
0
7
37
1.93
0.95
1.9
3.5
—
—
—
0
0
30
221
1.44
0.95
1.7
1.7
1.7
1.2
mg/l
0.30
24
170
74
646
1.27
0.76
4.5
3.6
20.7
24.6
%
1.43
34
295
5
27
1.88
0.69
1.0
1.3
—
—
—
0
0
29
228
1.33
0.64
3.3
2.2
—
—
—
0
0
9
139
0.63
0.64
2.1
2.5
6.9
9.3
ug/l
—
9
123
51
434
1.26
0.63
1.8
2.0
86.7
91.5
pmol/l
0.26
25
251
22
166
1.38
0.63
4.7
2.7
0.2
0.6
e6/l
1.03
13
87
18
131
1.42
0.62
1.4
1.8
—
—
—
0
0
115
1073
1.26
0.61
17.6
13.3
42.3
41.6
%
0.64
79
755
11
74
1.52
0.55
1.7
1.5
—
—
—
0
0
56
490
1.22
0.53
4.3
3.3
0.0
0.0
estimate
0.00
15
77
89
816
1.21
0.52
4.3
3.6
11.2
10.7
mm/h
0.16
84
743
56
492
1.21
0.51
5.4
4.5
0.0
0.0
estimate
0.00
15
79
16
121
1.36
0.46
2.6
2.8
1.8
1.9
mmol/l
—
10
91
11
148
0.72
0.41
7.5
8.3
—
—
—
0
0
56
502
1.18
0.40
4.3
3.3
0.0
0.0
estimate
0.00
14
69
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
10
72
1.41
0.38
1.1
1.7
—
—
—
0
0
74
689
1.14
0.31
2.8
2.9
—
—
—
0
0
45
405
1.15
0.31
4.5
3.4
—
—
—
0
0
22
187
1.20
0.28
4.1
2.5
0.5
1.0
e6/l
0.74
13
108
25
218
1.17
0.25
1.8
1.8
1332.8
1194.8
nmol/l
0.14
18
167
9
77
1.18
0.25
5.3
4.0
5.5
5.1
kpa
—
9
72
111
1072
1.12
0.22
18.1
11.3
82.1
81.2
ml/min/173m2
0.14
98
867
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.6
—
—
—
0
0
0
13
0.00
0.21
0.0
1.6
—
—
—
0
0
21
184
1.16
0.20
2.1
1.8
—
—
—
0
0
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
28
252
1.13
0.19
1.7
1.8
423.0
27404230.9
pmol/l
0.50
22
208
103
1000
1.09
0.15
3.6
3.5
1.9
2.0
mu/l
0.74
93
893
110
1128
0.92
0.15
4.5
4.6
6.0
6.1
mmol/l
0.49
103
1013
8
100
0.79
0.14
1.4
1.8
—
—
—
0
0
112
1095
1.08
0.13
5.3
6.4
40.3
40.7
mmol/mol
0.21
104
1018
16
143
1.13
0.12
1.3
1.5
—
—
—
0
0
5
46
1.09
0.09
1.0
1.0
—
—
—
0
0
7
66
1.06
0.08
2.1
1.8
1.1
1.4
%
—
7
66
11
98
1.13
0.08
3.4
3.8
301.4
235.8
ng/l
0.15
11
90
8
73
1.10
0.07
5.0
3.9
1.2
1.9
mmol/l
—
8
53
8
73
1.10
0.07
1.6
1.4
—
—
—
0
0
119
1175
1.05
0.06
3.9
4.5
4.5
4.4
mmol/l
0.32
110
1085
127
1256
1.06
0.06
11.6
8.5
27.8
30.0
u/l
0.94
127
1198
118
1167
1.04
0.05
3.9
4.5
1.3
1.3
mmol/l
0.36
109
1070
113
1140
0.97
0.03
3.5
4.1
1.3
1.3
mmol/l
0.13
102
1043
77
761
1.02
0.02
2.9
2.7
15.3
14.9
pmol/l
0.61
71
667
119
1198
0.97
0.02
4.4
5.0
2.7
2.7
mmol/l
0.04
111
1102
48
485
0.99
0.00
3.4
3.7
48.6
55.7
ng/l
0.11
36
348
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
37.5
—
0
6
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
6
68
0.88
0.00
7.5
4.1
62.5
85.9
ng/l
—
6
59
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_TESTIS_EXALLC – Benign neoplasm: Testis
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).